CD274 and cervical carcinoma: Among those, ERBB2, CD274 (PD-L1), and PDCD1LG2 (PD-L2) had amplifications that highlight the potential for clinical trials of ERBB2 inhibitors and immunotherapeutic strategies for a subset of cervical cancers [10,101].